Basic and clinical evaluation of carindacillin for complicated urinary tract infection caused by Pseudomonas aeruginosa

We evaluated the antibacterial activity and efficacy of carindacillin (CIPC), a synthetic penicillin, in the urological field. 1) Antimicrobial activities: Statistical studies were performed on Psudomonas aeruginosa isolated from patients with urinary tract infection from 1983 to 1991. Antimicrobial activities of new quinolones against these strains were annually reduced both in Muller-Hinton broth (MHB) and in artifical urine (AU). Antimicrobial activities of new quinolones in AU were more reduced than those in MHB, but the antimicrobial activities of CIPC were less reduced in both MHB and AU than those of the new quinolones. It was considered that the antimicrobial activities of the new quinolones were reduced due to low pH and high concentrations of magnesium and calcium in AU. 2) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 61.9% (13/21). Bacteriologically, 21 of 34 strains (61.8%) isolated were eradicated. The eradication rate for P. aeruginosa was 57.1% (12/21). 3) Side effects: No clinical side effects or abnormal laboratory changes were observed. Based on the above results, CIPC might be useful in the treatment of urinary tract infection caused by P. aeruginosa.